Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,686,728
  • Shares Outstanding, K 109,890
  • Annual Sales, $ 13,117 M
  • Annual Income, $ 3,954 M
  • EBIT $ 3,973 M
  • EBITDA $ 4,394 M
  • 60-Month Beta 0.15
  • Price/Sales 6.24
  • Price/Cash Flow 17.21
  • Price/Book 2.79

Options Overview Details

View History
  • Implied Volatility 29.33% ( -0.32%)
  • Historical Volatility 30.99%
  • IV Percentile 79%
  • IV Rank 61.34%
  • IV High 36.83% on 10/21/24
  • IV Low 17.43% on 06/12/24
  • Put/Call Vol Ratio 0.34
  • Today's Volume 222
  • Volume Avg (30-Day) 2,113
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 39,574
  • Open Int (30-Day) 39,151

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 9.74
  • Number of Estimates 10
  • High Estimate 11.62
  • Low Estimate 8.67
  • Prior Year 10.18
  • Growth Rate Est. (year over year) -4.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
736.01 +0.12%
on 11/20/24
972.74 -24.24%
on 10/22/24
-231.58 (-23.91%)
since 10/21/24
3-Month
736.01 +0.12%
on 11/20/24
1,211.20 -39.16%
on 08/27/24
-448.41 (-37.83%)
since 08/21/24
52-Week
736.01 +0.12%
on 11/20/24
1,211.20 -39.16%
on 08/27/24
-61.91 (-7.75%)
since 11/21/23

Most Recent Stories

More News
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license application (sBLA) seeking approval of Dupixent for the treatment of chronic spontaneous...

GILD : 88.40 (-0.26%)
REGN : 739.76 (-0.48%)
PFE : 24.84 (-0.40%)
SNY : 47.80 (+0.04%)
Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -1.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.40%. Stocks retreated...

AMAT : 172.62 (+1.49%)
IPG : 28.46 (+0.28%)
AVGO : 161.47 (-1.09%)
CNP : 31.38 (+0.06%)
D : 57.87 (+0.12%)
TTD : 123.22 (-0.55%)
$IUXX : 20,579.05 (-0.43%)
AMGN : 285.72 (-0.75%)
BNTX : 103.73 (+1.56%)
ASML : 653.18 (-0.80%)
ZNZ24 : 109-270 (+0.14%)
LNT : 62.36 (+0.21%)
Regeneron and Sanofi Announce FDA Acceptance of Dupixent Resubmission for Treating Chronic Spontaneous Urticaria with New Pivotal Data

Dupixent's resubmission for FDA review includes pivotal data showing significant reduction in itch and hive activity for CSU patients.Quiver AI SummaryRegeneron Pharmaceuticals and Sanofi have announced...

REGN : 739.76 (-0.48%)
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

REGN : 739.76 (-0.48%)
2 Top Growth Stocks to Buy on the Dip

Their recent issues are nothing to fret over for investors focused on the long game.

LLY : 744.33 (-1.21%)
REGN : 739.76 (-0.48%)
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

REGN : 739.76 (-0.48%)
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales

Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 17 cents. The company reported earnings of 10 cents...

BAYRY : 5.0550 (-1.65%)
JNJ : 153.30 (+0.12%)
REGN : 739.76 (-0.48%)
Regeneron Announces Investor Conference Presentations

REGN : 739.76 (-0.48%)
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt

Check out these three stocks with financial metrics showing recession resistance and underlying business dynamics to back them up.

INSW : 41.24 (-1.50%)
REGN : 739.76 (-0.48%)
RLI : 177.19 (+0.67%)
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.

SMCI : 27.16 (+5.27%)
IDXX : 412.83 (-1.38%)
REGN : 739.76 (-0.48%)
MRNA : 36.91 (-0.08%)
DELL : 135.19 (+0.92%)
ASML : 653.18 (-0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 765.36
2nd Resistance Point 758.03
1st Resistance Point 750.69
Last Price 739.76
1st Support Level 736.01
2nd Support Level 728.67
3rd Support Level 721.33

See More

52-Week High 1,211.20
Fibonacci 61.8% 1,029.68
Fibonacci 50% 973.60
Fibonacci 38.2% 917.53
Last Price 739.76
52-Week Low 736.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar